Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 22.10
Bid: 22.00
Ask: 22.20
Change: -0.15 (-0.67%)
Spread: 0.20 (0.91%)
Open: 22.25
High: 22.50
Low: 22.10
Yest. Close: 22.25
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

TRADING UPDATES: Caerus, Bezant pick Cyprus asset; TomCo buys JV

TRADING UPDATES: Caerus, Bezant pick Cyprus asset; TomCo buys JV

26 Aug 21 12:53

Scancell gets MHRA approval for Modi-1 clinical trial

(Sharecast News) - Immunotherapy developer Scancell announced on Thursday that the UK Medicines and Healthcare products Regulatory Authority (MHRA) has approved the clinical trial application to initiate the first-in-human phase 1 and 2 clinical study of 'Modi-1'.

26 Aug 21 12:38

Scancell chooses needle-free tech for Covid vaccine candidates

(Sharecast News) - Cancer and infectious disease immunotherapy developer Scancell has selected the PharmaJet needle-free injection system to administer its two SARS-CoV-2 vaccine candidates for Covid-19, 'SCOV1' and 'SCOV2', in its 'COVIDITY' phase 1 clinical trial, it announced on Tuesday.

17 Aug 21 15:32

DIRECTOR DEALINGS: Harbour Energy CEO for Europe buys 100,000 shares

DIRECTOR DEALINGS: Harbour Energy CEO for Europe buys 100,000 shares

30 Jul 21 14:24

TRADING UPDATES: Salt Lake funding talks; Resolute cuts output outlook

TRADING UPDATES: Salt Lake funding talks; Resolute cuts output outlook

29 Jul 21 22:08

IN BRIEF: Scancell turns once again to Durrant to lead company

IN BRIEF: Scancell turns once again to Durrant to lead company

28 Jul 21 22:00

Scancell makes progress with 'Covidity' trial plans

(Sharecast News) - Immunotherapy developer Scancell updated the market on 'Covidity' clinical trial plans, and the publication of preclinical data on two vaccine candidates from the research programme.

22 Jun 21 15:21

IN BRIEF: Scancell plans new Covid vaccine trial in South Africa, UK

IN BRIEF: Scancell plans new Covid vaccine trial in South Africa, UK

22 Jun 21 12:14

IN BRIEF: Scancell Non-Exec Director Martin Diggle buys more shares

IN BRIEF: Scancell Non-Exec Director Martin Diggle buys more shares

7 Jun 21 13:58

AIM WINNERS & LOSERS: NetScientific surges on Astra Covid test pact

AIM WINNERS & LOSERS: NetScientific surges on Astra Covid test pact

7 Jun 21 10:38

IN BRIEF: Scancell Non-Exec Director Martin Diggle buys 400,000 shares

IN BRIEF: Scancell Non-Exec Director Martin Diggle buys 400,000 shares

30 Apr 21 14:30

IN BRIEF: Associate Of Scancell Director Sells GBP109,000 In Shares

IN BRIEF: Associate Of Scancell Director Sells GBP109,000 In Shares

19 Feb 21 20:13

IN BRIEF: Scancell Non-Exec Director Diggle Sells 1.3 Million Shares

IN BRIEF: Scancell Non-Exec Director Diggle Sells 1.3 Million Shares

19 Feb 21 12:40

IN BRIEF: Scancell Non-Exec Director Diggle Sells GBP95,000 In Shares

IN BRIEF: Scancell Non-Exec Director Diggle Sells GBP95,000 In Shares

17 Feb 21 16:22

Scancell ends clinical development partnership with Cancer Research UK

(Sharecast News) - Novel immunotherapy developer Scancell updated the market on its SCIB2 clinical development partnership with Cancer Research UK on Wednesday, reporting that due to the impact of the Covid-19 pandemic and Cancer Research UK's re-evaluation of its collaboration model, the parties had agreed to end their clinical development partnership.

3 Feb 21 14:53

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.